**LOGO GOES HERE**

**[insert date]**

**[insert name and address**]

Providing clinicians with the high-quality clinical information they need is our central focus. To help you better assess your bariatric patients, **(INSERT FACILITY NAME)** recently acquired the ACUSON Sequoia™ ultrasound system. The ACUSON Sequoia addresses the bariatric population's unique needs through specialty transducers and industry-leading technology.

High BMI patients can challenge an imaging department’s ability to obtain diagnostic quality exams. With its industry-first Deep Abdominal Transducer (DAX), ACUSON Sequoia enables users to confidently image high BMI patients without sacrificing image quality, which limits the need for repeat scans and reduces unclear diagnoses. Along with the DAX transducer, we are now offering Ultrasound Derived Fat Fraction (UDFF) to complement our routine ultrasounds. UDFF quantifies the amount of fat contained within a patient's liver, quickly and painlessly, during an abdominal ultrasound. This newly acquired technology provides non-invasive, cost-effective access to quantitative data needed to successfully evaluate the liver and treat bariatric patients.

**Improve** **patient outcomes with early detection**

Early assessment and characterization of liver steatosis is key to overall disease management and improved patient outcomes. In a study of more than 8 million people, obesity was present in 51% of patients with Nonalcoholic fatty liver disease and 82% with Nonalcoholic steatohepatitis.1 Prolonged and continuous fat build-up within the hepatocytes creates a cycle of constant injury and repair within the liver. This persistent cycle can progress to more severe and permanent liver conditions. Early detection of hepatic steatosis improves the chances of managing or reversing the condition before irreversible changes occur.2

**Offering** **a non-invasive method to assess liver fat content**

Conventional ultrasound provides a qualitative assessment of hepatic steatosis, which can be subjective and lead to increased variability. UDFF eliminates variability by providing a

quantitative, numerical evaluation of liver fat. The ACUSON Sequoia is the only ultrasound technology to classify hepatic steatosis as an index value greater than 5%\*. UDFF delivers similar clinical utility to MRI Proton density Fat Fraction for determining hepatic steatosis without the high cost or limitations associated with MRI. With UDFF, physicians now have a new, non-invasive, cost-effective test to help manage adult patients\*\* with hepatic steatosis.

We are proud to provide this innovative system to you and your patients. To learn more about the ACUSON Sequoia and how it may help your patients, please contact us at [phone number]

or visit siemens-healthineers.us/sequoia.

Best wishes,

[**INSERT** **Facility name]**

*\*Disclaimer \*As of November 22, 2021*

*\*\*When used as part of an overall assessment of hepatic steatosis.*

*1 Younossi Zobair M. Non-alcoholic fatty liver disease – A global*

*public health perspective. Journal of Hepatology. 2019 vol*

*70|531-544*

*2 Labyed & Milkowski 2021; JUM 39(12) p2427-2428, doi:*

*10.1002/jum.15364*